Close

Russia to present Sputnik V vaccine against coronavirus at United Nations

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Eli Lilly’s $3.5 Billion Manufacturing Campus Advances in Upper Macungie, Pennsylvania

A planned $3.5 billion pharmaceutical manufacturing campus in Upper...

Overcoming Resistance-Associated Substitutions (RASs) to Direct-Acting Antivirals

Alt tag: Scientific illustration of Hepatitis C virus interacting...

Genentech Completes Structural Framework at New NC Manufacturing Facility

Genentech raised the final beam of its new Holly...
- Advertisement -

Russia’s permanent mission to the UN and the Health Ministry will hold a presentation, which will provide detailed information on the Russian vaccine against the novel coronavirus disease (COVID-19), mission spokesman Fyodor Strzhizhovsky told Sputnik.

During a speech at the UN General Assembly in September, Russian President Vladimir Putin suggested that the organisation’s employees be provided with the Russian vaccine against coronavirus free of charge. Russia’s Permanent Representative to the UN Vassily Nebenzia, in turn, did not rule out that the vaccine developers would present it at the UN headquarters.

“On Wednesday, December 2, a presentation of the Russian Sputnik V vaccine will take place. Russian Health Minister Mikhail Murashko, Russia’s Permanent Representative to the UN Vassily Nebenzia, and head of the Russian Direct Investment Fund (RDIF) Kirill Dmitriyev will take part in the event,” Strzhizhovsky said.

He said a virtual event entitled “Sputnik V: Vaccine Against COVID-19” will be held on the sidelines of a special session of the UN General Assembly. During the meeting, detailed information on the Russian vaccine will be presented.

In August, Russia’s Health Ministry registered the world’s first vaccine for the prevention of COVID-19, developed by the Gamaleya Research Centre. It was named Sputnik V. The vaccine is based on a well-studied and validated human adenoviral vector platform, the important benefits of which are safety, efficacy and no long-term adverse effects.

>>>

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Latest stories

Related stories

Eli Lilly’s $3.5 Billion Manufacturing Campus Advances in Upper Macungie, Pennsylvania

A planned $3.5 billion pharmaceutical manufacturing campus in Upper...

Overcoming Resistance-Associated Substitutions (RASs) to Direct-Acting Antivirals

Alt tag: Scientific illustration of Hepatitis C virus interacting...

Genentech Completes Structural Framework at New NC Manufacturing Facility

Genentech raised the final beam of its new Holly...

Chugai Pharmaceutical and GSK Sign Exclusive License Agreement for Anti-Dengue Antibody AID351

Japan-based Chugai Pharmaceutical has entered into an exclusive license...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »